» Articles » PMID: 24528930

Evidence-based Prescribing of Drugs for Secondary Prevention of Acute Coronary Syndrome in Aboriginal and Non-Aboriginal Patients Admitted to Western Australian Hospitals

Overview
Journal Intern Med J
Specialty General Medicine
Date 2014 Feb 18
PMID 24528930
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To assess the level of evidence-based drug prescribing for acute coronary syndrome (ACS) at discharge from Western Australian (WA) hospitals and determine predictors of such prescribing in Aboriginal and non-Aboriginal patients.

Methods: All Aboriginal (2002-2004) and a random sample of non-Aboriginal (2003) hospital admissions with a principal diagnosis of ACS were extracted from the WA Hospital Morbidity Data Collection of WA Data Linkage System. Clinical information, history of co-morbidities and drugs were collected from medical notes by trained data collectors. Evidence-based prescribing (EBP) was defined as prescribing of aspirin, statin and beta-blocker or angiotensin-converting enzyme inhibitor/angiotensin II antagonist.

Results: Records for 1717 ACS patients discharged alive from hospitals were reviewed. The majority of patients (71%) had EBP, and there was no significant difference between Aboriginal and non-Aboriginal patients (70% vs 71%, P = 0.36). Conversely, a significantly higher proportion of Aboriginal patients had none of the drugs prescribed compared with non-Aboriginal patients (11% vs 7%, P < 0.01). EBP for ACS was independently associated with male sex (odds ratio (OR) 1.63, 95% confidence interval (CI) 1.26-2.11), previous admission for ACS (OR 1.83, 95% CI 1.39-2.42) and diabetes (OR 1.36, 95% CI 1.04-1.79). However, ACS patients living in regional and remote areas, attending district or private hospitals, or with a history of chronic obstructive pulmonary disease were significantly less likely to have ACS drugs prescribed at discharge.

Conclusions: Opportunity exists to improve prescribing of recommended drugs for ACS patients at discharge from WA hospitals in both Aboriginal and non-Aboriginal patients. Attention regarding pharmaceutical management post-ACS is particularly required for patients from rural and remote areas, and those attending district and private hospitals.

Citing Articles

The 'ABC' of respiratory disorders among adult Indigenous people: asthma, bronchiectasis and COPD among Aboriginal Australians - a systematic review.

Howarth T, Jersmann H, Majoni S, Mo L, Ben Saad H, Ford L BMJ Open Respir Res. 2023; 10(1).

PMID: 37451702 PMC: 10351270. DOI: 10.1136/bmjresp-2023-001738.


The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman.

Al-Hadithy D, Al-Maqbali J, Al-Riyami A, Al Zaabi M, Al-Zakwani I Pharmacy (Basel). 2023; 11(3).

PMID: 37218961 PMC: 10204429. DOI: 10.3390/pharmacy11030079.


Investigating disparity in access to Australian clinical genetic health services for Aboriginal and Torres Strait Islander people.

Luke J, Dalach P, Tuer L, Savarirayan R, Ferdinand A, McGaughran J Nat Commun. 2022; 13(1):4966.

PMID: 36002448 PMC: 9400572. DOI: 10.1038/s41467-022-32707-0.


Quantifying the role of modifiable risk factors in the differences in cardiovascular disease mortality rates between metropolitan and rural populations in Australia: a macrosimulation modelling study.

Alston L, Peterson K, Jacobs J, Allender S, Nichols M BMJ Open. 2017; 7(11):e018307.

PMID: 29101149 PMC: 5695309. DOI: 10.1136/bmjopen-2017-018307.


Validation study of GRACE risk scores in indigenous and non-indigenous patients hospitalized with acute coronary syndrome.

Bradshaw P, Katzenellenbogen J, Sanfilippo F, Hobbs M, Thompson P, Thompson S BMC Cardiovasc Disord. 2015; 15:151.

PMID: 26573571 PMC: 4647306. DOI: 10.1186/s12872-015-0138-6.